{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:32:38Z","timestamp":1788323558147,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.phrs.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T03:17:41Z","timestamp":1467688661000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Pharmacological aspects of the safety of gliflozins"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-4073","authenticated-orcid":false,"given":"Jean-Luc","family":"Faillie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.07.001_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","article-title":"Glucose transport families SLC5 and SLC50","volume":"34","author":"Wright","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.phrs.2016.07.001_bib0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2016.07.001_bib0015","doi-asserted-by":"crossref","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","article-title":"Glucose transport by human renal Na+\/d-glucose cotransporters SGLT1 and SGLT2","volume":"300","author":"Hummel","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0025","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","volume":"14","author":"Santer","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2013a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.07.001_bib0035","doi-asserted-by":"crossref","first-page":"32678","DOI":"10.1074\/jbc.271.51.32678","article-title":"Panayotova-Heiermann M, Wright EM. Biophysical characteristics of the pig kidney Na+\/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2","volume":"271","author":"Mackenzie","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.07.001_bib0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s002329900347","article-title":"Relationships between Na+\/glucose cotransporter (SGLT1) currents and fluxes","volume":"162","author":"Mackenzie","year":"1998","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0045","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2016.07.001_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2012.06.033","article-title":"A novel SGLT is expressed in the human kidney","volume":"690","author":"Kothinti","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0055","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/ndt\/gfq008","article-title":"Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region","volume":"25","author":"Pruijm","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2016.07.001_bib0060","first-page":"75","article-title":"Observations sur les proprietes febrifuges de la phloridzine","volume":"1","author":"de Koninck","year":"1836","journal-title":"Bull. Soc. Med. Gand"},{"key":"10.1016\/j.phrs.2016.07.001_bib0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.phrs.2016.07.001_bib0070","doi-asserted-by":"crossref","first-page":"C94","DOI":"10.1152\/ajpcell.1982.242.1.C94","article-title":"Development of a Na-dependent hexose transport in a cultured line of porcine kidney cells","volume":"242","author":"Amsler","year":"1982","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0075","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.07.001_bib0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/2229-516X.165363","article-title":"Sodium glucose co-transporter inhibitors \u2013 a new class of old drugs","volume":"5","author":"Malhotra","year":"2015","journal-title":"Int. J. Appl. Basic Med. Res."},{"issue":"Suppl","key":"10.1016\/j.phrs.2016.07.001_bib0085","first-page":"S14","article-title":"SGLT2 inhibitors: molecular design and potential differences in effect","volume":"2011","author":"Isaji","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2016.07.001_bib0090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2016.07.001_bib0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/17425255.2014.873788","article-title":"Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations","volume":"10","author":"Scheen","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0100","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1152\/ajplegacy.1973.224.3.552","article-title":"Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs","volume":"224","author":"Vick","year":"1973","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0105","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2016.07.001_bib0110","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2016.07.001_bib0115","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2016.07.001_bib0120","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.001_bib0125","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2016.07.001_bib0130","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2016.07.001_bib0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0140","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S2213-8587(15)00426-X","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Ceriello","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2016.07.001_bib0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.07.001_bib0155","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.07.001_bib0165","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2016.07.001_bib0170","author":"European Medicines Agency Invokana (canagliflozin)"},{"key":"10.1016\/j.phrs.2016.07.001_bib0175","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.4049\/jimmunol.181.5.3126","article-title":"Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa","volume":"181","author":"Palazzo","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0180","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.phrs.2016.07.001_bib0185","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm."},{"key":"10.1016\/j.phrs.2016.07.001_bib0190","unstructured":"US Food and Drug Administration. FDA briefing document: NDA 202293 dapagliflozin 5 and 10\u2009mg. July 19, 2011. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/Committees-MeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM262994.pdf."},{"key":"10.1016\/j.phrs.2016.07.001_bib0195","unstructured":"US Food and Drug Administration. FDA background document, BMS-512148 NDA 202293 dapagliflozin. 2013. http:\/\/www.fda.gov\/downloads\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm378079.pdf."},{"key":"10.1016\/j.phrs.2016.07.001_bib0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpuro0510","article-title":"Mechanisms of disease: the epidemiology of bladder cancer","volume":"3","author":"Pelucchi","year":"2006","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0205","doi-asserted-by":"crossref","first-page":"719578","DOI":"10.1155\/2014\/719578","article-title":"A review on the relationship between SGLT2 inhibitors and cancer","volume":"2014","author":"Lin","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13300-014-0053-3","article-title":"Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus","volume":"5","author":"Reilly","year":"2014","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.phrs.2016.07.001_bib0215","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1517\/14656566.2013.812632","article-title":"Dapagliflozin for the treatment of type 2 diabetes","volume":"14","author":"Abdul-Ghani","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2016.07.001_bib0220","unstructured":"US Food and Drug Administration. Advisory Committee Nonclinical Briefing Document. FDA briefing document: NDA 202293 dapagliflozin 5 and 10\u2009mg. July 19, 2011. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/Committees-MeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM262994.pdf."},{"key":"10.1016\/j.phrs.2016.07.001_bib0225","unstructured":"US Food and Drug Administration. FDA Briefing Document, NDA 204042 Canagliflozin tablets. Advisory Committee Meeting: 2013. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM334550.pdf."},{"key":"10.1016\/j.phrs.2016.07.001_bib0230","unstructured":"European Medicines Agency Summary of the risk management plan (RMP) for Jardiance (empagliflozin). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/002677\/WC500163291.pdf."},{"key":"10.1016\/j.phrs.2016.07.001_bib0235","unstructured":"US Food and Drug Administration. Jardiance (empagliflozin). Medical Review. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204629Orig1s000MedR.pdf."},{"key":"10.1016\/j.phrs.2016.07.001_bib0240","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2001.tb01175.x","article-title":"SGLT gene expression in primary lung cancers and their metastatic lesions","volume":"92","author":"Ishikawa","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.phrs.2016.07.001_bib0245","series-title":"EPAR Public Assessment Report","author":"European Medicines Agency Forxiga (dapagliflozin)","year":"2012"},{"key":"10.1016\/j.phrs.2016.07.001_bib0250","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2016.07.001_bib0255","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2016.07.001_bib0260","unstructured":"European Medicines Agency SGLT2 inhibitors. Opinion provided by Committee for Medicinal Products for Human Use. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors__20\/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use\/WC500203178.pdf."},{"key":"10.1016\/j.phrs.2016.07.001_bib0265","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2016.07.001_bib0270","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"Munro","year":"1973","journal-title":"Br. Med. J."},{"key":"10.1016\/j.phrs.2016.07.001_bib0275","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/1947-2714.157490","article-title":"Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosis","volume":"7","author":"Thawabi","year":"2015","journal-title":"N. Am. J. Med. Sci."},{"key":"10.1016\/j.phrs.2016.07.001_bib0280","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.07.001_bib0285","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.07.001_bib0290","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1172\/JCI111658","article-title":"Insulin within islets is a physiologic glucagon release inhibitor","volume":"74","author":"Maruyama","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.07.001_bib0295","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2016.07.001_bib0300","first-page":"156","article-title":"Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0)","volume":"27","author":"Oemar","year":"1987","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0305","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2016.07.001_bib0310","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1152\/ajplegacy.1955.184.1.91","article-title":"Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin","volume":"184","author":"Cohen","year":"1956","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0315","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2016.07.001_bib0320","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2016.07.001_bib0325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2016.07.001_bib0330","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0335","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2016.07.001_bib0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2016.07.001_bib0345","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0350","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2337\/diacare.14.3.220","article-title":"Central role of sodium in hypertension in diabetic subjects","volume":"14","author":"Weidmann","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2016.07.001_bib0355","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2016.07.001_bib0360","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/jcp.25286","article-title":"SGLT2 inhibitors: glucotoxicity and tumorigenesis downstream the renal proximal tubule","volume":"231","author":"Bertinat","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0365","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0002-8703(00)90325-9","article-title":"Diuretics and beta-blockers: is there a risk for dyslipidemia","volume":"139","author":"Weir","year":"2000","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2016.07.001_bib0370","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.phrs.2016.07.001_bib0375","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states","volume":"84","author":"Banerjee","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2016.07.001_bib0380","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.phrs.2016.07.001_bib0385","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.phrs.2016.07.001_bib0390","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2016.07.001_bib0395","unstructured":"EMA reviews diabetes medicine canagliflozin. Review follows data on toe amputations in ongoing study. 2016. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/SGLT2_inhibitors_(previously_Canagliflozin)\/human_referral_prac_000059.jsp&mid=WC0b01ac05805c516f."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816306363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816306363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T16:52:41Z","timestamp":1656780761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816306363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":79,"alternative-id":["S1043661816306363"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.07.001","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological aspects of the safety of gliflozins","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}